Table of Contents Author Guidelines Submit a Manuscript
International Journal of Breast Cancer
Volume 2012 (2012), Article ID 740353, 9 pages
http://dx.doi.org/10.1155/2012/740353
Research Article

PKC and ER Are Associated with Triple-Negative Breast Cancers in African American and Caucasian Patients

1Department of Biopharmaceutical Sciences, College of Pharmacy, University of Illinois at Chicago, 833 S. Wood Street, Chicago, IL 60612, USA
2Design and Analysis Core, Center for Clinical and Translational Science, University of Illinois, 914 S. Wood Street, Chicago, IL 60612, USA
3Department of Pathology, Rush University Medical Center, 1643 W. Congress Parkway, Murdock Building, Street 593, Chicago, IL 60612, USA

Received 22 July 2011; Accepted 18 December 2011

Academic Editor: Thelma Hurd

Copyright © 2012 Debra A. Tonetti et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. V. Brower, “Cancer disparities: disentangling the effects of race and genetics,” Journal of the National Cancer Institute, vol. 100, no. 16, pp. 1126–1129, 2008. View at Publisher · View at Google Scholar · View at Scopus
  2. K. Amend, D. Hicks, and C. B. Ambrosone, “Breast cancer in African-American women: differences in tumor biology from European-American women,” Cancer Research, vol. 66, no. 17, pp. 8327–8330, 2006. View at Publisher · View at Google Scholar · View at Scopus
  3. L. A. Carey, C. M. Perou, C. A. Livasy et al., “Race, breast cancer subtypes, and survival in the Carolina breast cancer study,” Journal of the American Medical Association, vol. 295, no. 21, pp. 2492–2502, 2006. View at Publisher · View at Google Scholar · View at Scopus
  4. J. J. Dignam, “The ongoing search for the sources of the breast cancer survival disparity,” Journal of Clinical Oncology, vol. 24, no. 9, pp. 1326–1328, 2006. View at Publisher · View at Google Scholar · View at Scopus
  5. J. E. Cunningham and W. M. Butler, “Racial disparities in female breast cancer in South Carolina: clinical evidence for a biological basis,” Breast Cancer Research and Treatment, vol. 88, no. 2, pp. 161–176, 2004. View at Google Scholar · View at Scopus
  6. R. T. Chlebowski, Z. Chen, G. L. Anderson et al., “Ethnicity and breast cancer: factors influencing differences in incidence and outcome,” Journal of the National Cancer Institute, vol. 97, no. 6, pp. 439–447, 2005. View at Publisher · View at Google Scholar · View at Scopus
  7. L. A. Stead, T. L. Lash, J. E. Sobieraj et al., “Triple-negative breast cancers are increased in black women regardless of age or body mass index,” Breast Cancer Research, vol. 11, no. 2, article R18, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. C. Rosse, M. Linch, S. Kermorgant, A. J. Cameron, K. Boeckeler, and P. J. Parker, “PKC and the control of localized signal dynamics,” Nature Reviews Molecular Cell Biology, vol. 11, no. 2, pp. 103–112, 2010. View at Publisher · View at Google Scholar · View at Scopus
  9. O. Konopatskaya and A. W. Poole, “Protein kinase Calpha: disease regulator and therapeutic target,” Trends in Pharmacological Sciences, vol. 31, no. 1, pp. 8–14, 2009. View at Google Scholar
  10. L. B. Frankel, A. E. Lykkesfeldt, J. B. Hansen, and J. Stenvang, “Protein Kinase C α is a marker for antiestrogen resistance and is involved in the growth of tamoxifen resistant human breast cancer cells,” Breast Cancer Research and Treatment, vol. 104, no. 2, pp. 165–179, 2007. View at Publisher · View at Google Scholar · View at Scopus
  11. D. A. Tonetti, M. Morrow, N. Kidwai, A. Gupta, and S. Badve, “Elevated protein kinase C alpha expression may be predictive of tamoxifen treatment failure,” British Journal of Cancer, vol. 88, no. 9, pp. 1400–1402, 2003. View at Publisher · View at Google Scholar · View at Scopus
  12. J. W. Assender, J. M. Gee, I. Lewis, I. O. Ellis, J. F. Robertson, and R. I. Nicholson, “Protein kinase C isoform expression as a predictor of disease outcome on endocrine therapy in breast cancer,” Journal of Clinical Pathology, vol. 60, no. 11, pp. 1216–1221, 2007. View at Publisher · View at Google Scholar · View at Scopus
  13. G. K. Lonne, L. Cornmark, I. O. Zahirovic, G. Landberg, K. Jirstrom, and C. Larsson, “PKCalpha expression is a marker for breast cancer aggressiveness,” Molecular Cancer, vol. 9, p. 76, 2010. View at Publisher · View at Google Scholar
  14. E. M. Fox, R. J. Davis, and M. A. Shupnik, “ERβ in breast cancer—onlooker, passive player, or active protector?” Steroids, vol. 73, no. 11, pp. 1039–1051, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. F. Novelli, M. Milella, E. Melucci et al., “A divergent role for estrogen receptor-beta in node-positive and node-negative breast cancer classified according to molecular subtypes: an observational prospective study,” Breast Cancer Research, vol. 10, no. 5, article R74, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. N. Honma, R. Horii, T. Iwase et al., “Clinical importance of estrogen receptor-β evaluation in breast cancer patients treated with adjuvant tamoxifen therapy,” Journal of Clinical Oncology, vol. 26, no. 22, pp. 3727–3734, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. A. M. Shaaban, A. R. Green, S. Karthik et al., “Nuclear and cytoplasmic expression of ERbeta1, ERbeta2, and ERbeta5 identifies distinct prognostic outcome for breast cancer patients,” Clinical Cancer Research, vol. 14, no. 16, pp. 5228–5235, 2008. View at Google Scholar
  18. G. P. Skliris, E. Leygue, L. Curtis-Snell, P. H. Watson, and L. C. Murphy, “Expression of oestrogen receptor-β in oestrogen receptor-α negative human breast tumours,” British Journal of Cancer, vol. 95, no. 5, pp. 616–626, 2006. View at Publisher · View at Google Scholar · View at Scopus
  19. A. M. Sotoca, H. van den Berg, J. Vervoort et al., “Influence of cellular ERalpha/ERbeta ratio on the ERalpha-agonist induced proliferation of human T47D breast cancer cells,” The Journal of Toxicological Sciences, vol. 105, no. 2, pp. 303–311, 2008. View at Google Scholar
  20. V. Speirs and R. A. Walker, “New perspectives into the biological and clinical relevance of oestrogen receptors in the human breast,” Journal of Pathology, vol. 211, no. 5, pp. 499–506, 2007. View at Publisher · View at Google Scholar · View at Scopus
  21. J. T. Moore, D. D. McKee, K. Slentz-Kesler et al., “Cloning and characterization of human estrogen receptor β isoforms,” Biochemical and Biophysical Research Communications, vol. 247, no. 1, pp. 75–78, 1998. View at Publisher · View at Google Scholar · View at Scopus
  22. S. Mann, R. Laucirica, N. Carlson et al., “Estrogen receptor beta expression in invasive breast cancer,” Human Pathology, vol. 32, no. 1, pp. 113–118, 2001. View at Publisher · View at Google Scholar · View at Scopus
  23. Y. Umekita, M. Souda, Y. Ohi et al., “Expression of wild-type estrogen receptor β protein in human breast cancer: specific correlation with HER2/neu overexpression,” Pathology International, vol. 56, no. 8, pp. 423–427, 2006. View at Publisher · View at Google Scholar · View at Scopus
  24. D. A. Tonetti, R. Rubenstein, M. DeLeon et al., “Stable transfection of an estrogen receptor beta cDNA isoform into MDA-MB-231 breast cancer cells,” Journal of Steroid Biochemistry and Molecular Biology, vol. 87, no. 1, pp. 47–55, 2003. View at Publisher · View at Google Scholar · View at Scopus
  25. D. C. Allred, G. M. Clark, R. Elledge et al., “Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer,” Journal of the National Cancer Institute, vol. 85, no. 3, pp. 200–206, 1993. View at Google Scholar · View at Scopus
  26. C. Borner, R. Wyss, R. Regazzi, U. Eppenberger, and D. Fabbro, “Immunological quantitation of phopholipid/Ca2+-dependent protein kinase of human mammary carcinoma cells: inverse relationship to estrogen receptors,” International Journal of Cancer, vol. 40, no. 3, pp. 344–348, 1987. View at Google Scholar · View at Scopus
  27. D. B. Fournier, M. Chisamore, J. R. Lurain, A. W. Rademaker, V. C. Jordan, and D. A. Tonetti, “Protein kinase C alpha expression is inversely related to ER status in endometrial carcinoma: possible role in AP-1-mediated proliferation of ER-negative endometrial cancer,” Gynecologic Oncology, vol. 81, no. 3, pp. 366–372, 2001. View at Publisher · View at Google Scholar · View at Scopus
  28. J. Hartman, A. Strom, and J. A. Gustafsson, “Estrogen receptor beta in breast cancer-diagnostic and therapeutic implications,” Steroids, vol. 74, no. 8, pp. 635–641, 2009. View at Publisher · View at Google Scholar · View at Scopus
  29. V. Speirs, C. Malone, D. S. Walton, M. J. Kerin, and S. L. Atkin, “Increased expression of estrogen receptor β mRNA in tamoxifen-resistant breast cancer patients,” Cancer Research, vol. 59, no. 21, pp. 5421–5424, 1999. View at Google Scholar · View at Scopus
  30. H. Dotzlaw, E. Leygue, P. H. Watson, and L. C. Murphy, “Estrogen receptor-β messenger RNA expression in human breast tumor biopsies: relationship to steroid receptor status and regulation by progestins,” Cancer Research, vol. 59, no. 3, pp. 529–532, 1999. View at Google Scholar · View at Scopus
  31. D. Roychowdhury and M. Lahn, “Antisense therapy directed to protein kinase C-alpha (Affinitak, LY900003/ISIS 3521): potential role in breast cancer,” Semin Oncol, vol. 30, no. 2, supplement 3, pp. 30–33, 2003. View at Google Scholar
  32. J. N. Ingle, “Estrogen as therapy for breast cancer,” Breast Cancer Research, vol. 4, no. 4, pp. 133–136, 2002. View at Publisher · View at Google Scholar · View at Scopus
  33. R. L. Mahtani, A. Stein, and C. L. Vogel, “High-dose estrogen as salvage hormonal therapy for highly refractory metastatic breast cancer: a retrospective chart review,” Clinical Therapeutics, vol. 31, part 2, pp. 2371–2378, 2009. View at Google Scholar · View at Scopus
  34. P. P. Peethambaram, J. N. Ingle, V. J. Suman, L. C. Hartmann, and C. L. Loprinzi, “Randomized trial of diethylstilbestrol vs. tamoxifen in postmenopausal women with metastatic breast cancer. An updated analysis,” Breast Cancer Research and Treatment, vol. 54, no. 2, pp. 117–122, 1999. View at Publisher · View at Google Scholar · View at Scopus
  35. M. J. Ellis, F. Gao, F. Dehdashti et al., “Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized study,” Journal of the American Medical Association, vol. 302, no. 7, pp. 774–780, 2009. View at Publisher · View at Google Scholar · View at Scopus
  36. M. J. Chisamore, Y. Ahmed, D. J. Bentrem, V. C. Jordan, and D. A. Tonetti, “Novel antitumor effect of estradiol in athymic mice injected with a T47D breast cancer cell line overexpressing protein kinase Cα,” Clinical Cancer Research, vol. 7, no. 10, pp. 3156–3165, 2001. View at Google Scholar · View at Scopus
  37. Y. Zhang, H. Zhao, S. Asztalos, M. Chisamore, Y. Sitabkhan, and D. A. Tonetti, “Estradiol-induced regression in T47D:A18/PKCα tumors requires the estrogen receptor and interaction with the extracellular matrix,” Molecular Cancer Research, vol. 7, no. 4, pp. 498–510, 2009. View at Publisher · View at Google Scholar · View at Scopus
  38. E. R. Levin and R. J. Pietras, “Estrogen receptors outside the nucleus in breast cancer,” Breast Cancer Research and Treatment, vol. 108, no. 3, pp. 351–361, 2008. View at Publisher · View at Google Scholar · View at Scopus
  39. I. Poola, R. Clarke, R. DeWitty, and L. D. Leffall, “Functionally active estrogen receptor isoform profiles in the breast tumors of African American women are different from the profiles in breast tumors of Caucasian women,” Cancer, vol. 94, no. 3, pp. 615–623, 2002. View at Publisher · View at Google Scholar · View at Scopus
  40. I. Poola, S. A. Fuqua, R. L. De Witty, J. Abraham, J. J. Marshallack, and A. Liu, “Estrogen receptor alpha-negative breast cancer tissues express significant levels of estrogen-independent transcription factors, ERbeta1 and ERbeta5: potential molecular targets for chemoprevention.,” Clinical Cancer Research, vol. 11, no. 20, pp. 7579–7585, 2005. View at Google Scholar
  41. S. K. Gruvberger-Saal, P. O. Bendahl, L. H. Saal et al., “Estrogen receptor β expression is associated with tamoxifen response in ERα-negative breast carcinoma,” Clinical Cancer Research, vol. 13, no. 7, pp. 1987–1994, 2007. View at Publisher · View at Google Scholar · View at Scopus